NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis

Alnylam Pharmaceuticals, Inc. (ALNY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALNY

$225.10

−$5.61 (−2.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALNY with… →

ALNY Key Statistics

As of Oct 21, 2026
Trading
Open
$227.86
Previous Close
$230.71
Day's Range
224.89–230.84
52-Week Range
197.81–485.36
Volume
1.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.27
Valuation
Market Cap
$30.12B
P/E Ratio
37.96
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
18.22
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.30
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.27
EPS (ttm)Profit attributable to each share over the last twelve months.
5.93
Financials (FY)
Revenue (FY)
$3.71B+65.19%
Net Income (FY)
$313.75M
Profit marginThe share of revenue left as profit after all costs and taxes.
16.13%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
133.81M
1-Year Return
−52.51%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
1.73M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALNY closed at $225.10, −52.51% over 1 year.

Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of $30.12B.

In fiscal 2025, ALNY reported revenue of $3.71B.

ALNY Stock Return by Calendar Year

Alnylam Pharmaceuticals, Inc. (ALNY) 10-year return: what $10,000 became

1 year
$10,000 $4,749
−52.51%
5 years
$10,000 $11,016
+10.16%
10 years
$10,000 $61,385
+513.85%

If you had invested $10,000 in Alnylam Pharmaceuticals, Inc. (ALNY) 10 years ago, at the close on October 21, 2016, it would have been worth $61,385 at the close on October 21, 2026: +513.85% in total, +19.90% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.39%
2025+68.99%
2024+22.94%
2023−19.46%
2022+40.14%
2021+30.48%
2020+12.85%
2019+57.96%
2018−42.61%
2017+239.34%
2016 (partial year)−50.95%

As of October 21, 2026.

ALNY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.71B$313.75M8.4%
2024$2.25B−$278.16M−12.4%
2023$1.83B−$440.24M−24.1%
2022$1.04B−$1.13B−109.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.71B$3.03B$501.58M$313.75M8.4%
2024$2.25B$1.92B−$176.89M−$278.16M−12.4%
2023$1.83B$1.52B−$282.18M−$440.24M−24.1%
2022$1.04B$868.60M−$785.07M−$1.13B−109.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALNY Valuation vs Biotechnology Median

Median of 608 stocks
MetricALNYBiotechnology medianvs median
P/E37.9616.60129% above
P/S ratio6.2713.3053% below
Profit margin16.13%−38.31%54.4 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Alnylam Pharmaceuticals, Inc. (ALNY) carries a market capitalisation of $30.12B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 2,500 employees.

The 52-week range on file runs from $197.81 to $485.36. The most recent close on file for ALNY is $225.10, dated October 21, 2026. That is −$5.61 (−2.43%) against the previous close. The latest close sits 13.8% above that 52-week low.

Financial Health

In fiscal 2025, Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B. That is +65.19% against the prior fiscal year, when revenue was $2.25B. Net income for the same year was $313.75M. The reported profit margin is 16.13%. That is 54.4 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 5.93.

Across the 4 fiscal years on file, revenue moves from $1.04B in 2022 to $3.71B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 37.96. That is 128.67% above the Biotechnology median of 16.6. The forward P/E on file is 18.22. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.3. The price-to-sales ratio is 6.27. On price-to-sales that is 52.85% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −52.51%. Measured over 10 years, that is +19.90% a year compounded. The reported beta is 0.27. Daily returns over the trailing 10 years annualize to a volatility of 51.99%.

Growth & Income

No dividend is on file for ALNY.

The strongest complete calendar year on file is 2017 at +239.34%; the weakest is 2018 at −42.61%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the total return is −43.39%.

Peer Comparison

Alnylam Pharmaceuticals, Inc. (ALNY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alnylam Pharmaceuticals, Inc. ALNY $30.12B 38.0
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alnylam Pharmaceuticals, Inc. trades at a P/E of 38.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Visit website →